The effects of putative DNA repair inhibitors on DNA adduct levels and unscheduled DNA synthesis in rat hepatocytes exposed to 2-acetylaminofluorene.
The enzymology of DNA repair is currently under active investigation. The purpose of the present study was to examine the involvement of a number of enzymes (DNA polymerase alpha and beta, DNA topoisomerase II and ribonucleotide reductase) in the repair of chemically induced DNA damage in a mammalian cell system. This was done by studying the effects of inhibitors of these enzymes on the levels of 2-acetylaminofluorene (2-AAF)-DNA adducts and on the induction of UDS in primary cultures of rat hepatocytes exposed to the carcinogen in vitro. The results obtained with aphidicolin (an inhibitor of DNA polymerase alpha) show that the binding of 2-AAF to cellular DNA was significantly higher in samples exposed to this compound. Moreover, induction of UDS by 2-AAF was completely blocked in the presence of this compound. Dideoxythymidine, a DNA polymerase beta inhibitor, led to complex results. It produced a reduced DNA-specific activity due to [3H]2-AAF adduct formation as well as a diminished but still detectable UDS response in the presence of 2-AAF. Inhibitors of DNA topoisomerase II (nalidixic acid) and ribonucleotide reductase (hydroxyurea) did not cause any statistically significant change in the accumulation of 2-AAF adducts nor did they affect the induction of UDS. The data clearly suggest that DNA polymerase alpha participates in the repair of 2-AAF adducts in hepatocytes. In addition, neither DNA topoisomerase II activity, nor limitations in the precursor nucleotide pools appear to be critical factors in this process.
Jutras
D
D
Department of Chemistry, Université du Québec à Montréal, Canada.
Marion
M
M
Denizeau
F
F
D015073:2-Acetylaminofluorene / Q000633:toxicity*; D000818:Animals; D016590:Aphidicolin; D002478:Cells, Cultured; D003561:Cytarabine / Q000494:pharmacology; D004249:DNA Damage; D004260:DNA Repair / Q000187:drug effects*; D015224:Dideoxynucleosides / Q000494:pharmacology; D004224:Diterpenes / Q000494:pharmacology; D006918:Hydroxyurea / Q000494:pharmacology; D066298:In Vitro Techniques; D008099:Liver / Q000166:cytology; D008297:Male; D009268:Nalidixic Acid / Q000494:pharmacology; D019384:Nucleic Acid Synthesis Inhibitors; D051381:Rats; D059004:Topoisomerase I Inhibitors
D015224:Dideoxynucleosides; D004224:Diterpenes; D019384:Nucleic Acid Synthesis Inhibitors; D059004:Topoisomerase I Inhibitors; D003561:Cytarabine; C019336:2',3'-dideoxythymidine; D016590:Aphidicolin; D009268:Nalidixic Acid; D015073:2-Acetylaminofluorene; D006918:Hydroxyurea